Article
Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing.
Lung cancer (Amsterdam, Netherlands) - 1 Oct 2020
Christopoulos P, Kirchner M, Roeper J, Saalfeld F, Janning M, Bozorgmehr F, Magios N, Kazdal D, Volckmar A L, Brückner L M, Bochtler T, Kriegsmann M, Endris V, Penzel R, Kriegsmann K, Eichhorn M, Herth F J F, Heussel C P, El Shafie R A, Schneider M A, Muley T, Meister M, Faehling M, Fischer J R, Heukamp L, Schirmacher P, Bischoff H, Wermke M, Loges S, Griesinger F, Stenzinger A, Thomas M
Abstract excerpt
OBJECTIVE: Panel-based next-generation sequencing (NGS) is increasingly used for the diagnosis of EGFR-mutated non-small-cell lung cancer (NSCLC) and could improve risk assessment in combination with clinical parameters. MATERIALS AND METHODS: To this end, we retrospectively analyzed the outcome of 400 tyrosine kinase inhibitor (TKI)-treated EGFR+ NSCLC patients with validation of results in an independent cohort...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.